Uli Bialucha

Company: Xilio Therapeutics Inc.

Job title: Chief Scientific Officer

Seminars:

Ensuring Translational Success by Futureproofing Your Program: Preclinical Model Selection & Predictive Biomarker Screening 1:00 pm

Dive into discussions on how to maximize the developability of your pre-clinical cytokine efforts through to the clinic and beyond. Explore the intricacies of preclinical models for cytokine therapeutic development and start early thinking for patient selection and dose profiling. Join this workshop to: Navigate what steps can be taken in early development to improve…Read more

day: Pre-Conference Workshop Day

Emerging Learnings From Pre-Clinical Combinations of Tumor-Activated Cytokines With Other Immune-oncology Agents 11:00 am

Revealing the scientific rationale for using cytokines in combination Addressing challenges in combining systemically active cytokines Exploring Pre-clinical data supporting use of Xilio’s tumor-activated cytokines in combination with other IO agentsRead more

day: Conference Day Two

XTX501, a Tumor-Activated PD1/IL2 Bispecific Molecule, Designed to Stimulate & Expand Antigen-Experienced T cells in the Tumor Microenvironment 11:40 am

Design of XTX501 and key components Rationale for targeting IL-2 to PD1-positive T cells and importance of masking Overview of preclinical data including PK and tolerability in non-human primatesRead more

day: Conference Day One